The Pfizer Advantage: High Dividend Yield, JN.1 Variant, And Therapeutic Innovations

Summary:

  • Pfizer is one of the largest American pharmaceutical companies, developing medicines and vaccines using cutting-edge technologies to save and improve the lives of millions worldwide.
  • Pfizer’s revenue for the three months that ended in 2023 was about $13.23 billion, up 3.9% from the previous quarter, but it missed analysts’ expectations by $230 million.
  • On December 14, 2023, Pfizer strengthened its position in the fast-growing cancer drugs market by completing its $43 billion acquisition of Seagen.
  • The company’s dividend yield is 5.92%, outperforming its main competitors in the pharmaceutical industry, such as Merck, Bristol-Myers Squibb, AbbVie, and AstraZeneca.
  • I’m initiating coverage of Pfizer with a “buy” rating.

Trading Begins As The Markets Open Monday Morning

Michael M. Santiago

Pfizer (NYSE:PFE) is a blue chip dividend stock whose medications, product candidates, and vaccines play one of the key roles in the fight against various types of cancer, viruses, immuno-inflammatory, infectious, cardiovascular, and rare diseases.

Thesis

Since


Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.


Leave a Reply

Your email address will not be published. Required fields are marked *